These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 15142864)

  • 1. Effect of pravastatin on low-density lipoprotein oxidation and myocardial perfusion in young adults with type 1 diabetes.
    Janatuinen T; Knuuti J; Toikka JO; Ahotupa M; Nuutila P; Rönnemaa T; Raitakari OT
    Arterioscler Thromb Vasc Biol; 2004 Jul; 24(7):1303-8. PubMed ID: 15142864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease.
    Ling MC; Ruddy TD; deKemp RA; Ukkonen H; Duchesne L; Higginson L; Williams KA; McPherson R; Beanlands R
    Am Heart J; 2005 Jun; 149(6):1137. PubMed ID: 15976803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults.
    Janatuinen T; Laaksonen R; Vesalainen R; Raitakari O; Lehtimäki T; Nuutila P; Knuuti J
    J Cardiovasc Pharmacol; 2001 Oct; 38(4):561-8. PubMed ID: 11588526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men.
    Lehtimäki T; Laaksonen R; Janatuinen T; Vesalainen R; Nuutila P; Mattila K; Ilveskoski E; Luomala M; Saikku P; Knuuti J; Hurme M
    Pharmacogenetics; 2003 Oct; 13(10):633-9. PubMed ID: 14515062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels.
    Mostaza JM; Gomez MV; Gallardo F; Salazar ML; Martín-Jadraque R; Plaza-Celemín L; Gonzalez-Maqueda I; Martín-Jadraque L
    J Am Coll Cardiol; 2000 Jan; 35(1):76-82. PubMed ID: 10636263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of myocardial blood flow by lipid-lowering therapy with pravastatin is modulated by apolipoprotein E genotype.
    Ilveskoski E; Lehtimäki T; Laaksonen R; Janatuinen T; Vesalainen R; Nuutila P; Laippala P; Karhunen PJ; Knuuti J
    Scand J Clin Lab Invest; 2007; 67(7):723-34. PubMed ID: 17852827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
    Wassmann S; Faul A; Hennen B; Scheller B; Böhm M; Nickenig G
    Circ Res; 2003 Oct; 93(9):e98-103. PubMed ID: 14551237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial.
    Schwartz RG; Pearson TA; Kalaria VG; Mackin ML; Williford DJ; Awasthi A; Shah A; Rains A; Guido JJ
    J Am Coll Cardiol; 2003 Aug; 42(4):600-10. PubMed ID: 12932588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute hypoglycemia decreases myocardial blood flow reserve in patients with type 1 diabetes mellitus and in healthy humans.
    Rana O; Byrne CD; Kerr D; Coppini DV; Zouwail S; Senior R; Begley J; Walker JJ; Greaves K
    Circulation; 2011 Oct; 124(14):1548-56. PubMed ID: 21911786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study.
    Kunnas TA; Lehtimäki T; Laaksonen R; Ilveskoski E; Janatuinen T; Vesalainen R; Nuutila P; Karhunen PJ; Knuuti J; Nikkari ST
    J Mol Med (Berl); 2002 Dec; 80(12):802-7. PubMed ID: 12483466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats.
    Kobayashi T; Matsumoto T; Kamata K
    Br J Pharmacol; 2000 Sep; 131(2):231-8. PubMed ID: 10991915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy.
    Nieminen T; Knuuti J; Hämelahti P; Kähönen M; Laaksonen R; Janatuinen T; Vesalainen R; Nuutila P; Jokela H; Lehtimäki T
    Vascul Pharmacol; 2007; 47(2-3):113-7. PubMed ID: 17574929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
    Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
    Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia.
    van der Graaf A; Rodenburg J; Vissers MN; Hutten BA; Wiegman A; Trip MD; Stroes ES; Wijburg FA; Otvos JD; Kastelein JJ
    J Pediatr; 2008 Jun; 152(6):873-8. PubMed ID: 18492534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients.
    Gannagé-Yared MH; Azar RR; Amm-Azar M; Khalifé S; Germanos-Haddad M; Neemtallah R; Halaby G
    Metabolism; 2005 Jul; 54(7):947-51. PubMed ID: 15988706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifibrol as a model compound for a novel lipid-lowering mechanism of action.
    Berthold HK; Sudhop T; von Bergmann K; Gouni-Berthold I
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):364-72. PubMed ID: 20693157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
    Lewis JH; Mortensen ME; Zweig S; Fusco MJ; Medoff JR; Belder R;
    Hepatology; 2007 Nov; 46(5):1453-63. PubMed ID: 17668878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin.
    Murrow JR; Sher S; Ali S; Uphoff I; Patel R; Porkert M; Le NA; Jones D; Quyyumi AA
    J Clin Lipidol; 2012; 6(1):42-9. PubMed ID: 22264573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients.
    Chen MF; Hsu HC; Lee YT
    Cardiovasc Drugs Ther; 1997 Dec; 11(6):787-93. PubMed ID: 9512874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.